Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer

Urology

Volumn 86, Issue 5, 2015, Pages 852-861

  Saad, Fred ^a   Fizazi, Karim ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; APALUTAMIDE; AROMATASE INHIBITOR; BICALUTAMIDE; CYPROTERONE ACETATE; CYTOCHROME P450 FAMILY 17; DAROLUTAMIDE; DEGARELIX; DOCETAXEL; ENZALUTAMIDE; FLUTAMIDE; GALETERONE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; MIFEPRISTONE; NILUTAMIDE; SPIRONOLACTONE; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TAXOID;

ANDROGEN DEPRIVATION THERAPY; CANCER HORMONE THERAPY; CASTRATION RESISTANT PROSTATE CANCER; DRUG BINDING; DRUG EFFICACY; DRUG TARGETING; HUMAN; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW; CANCER STAGING; DISEASE FREE SURVIVAL; MALE; MORTALITY; PATHOLOGY; PREVENTION AND CONTROL; PROCEDURES; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK ASSESSMENT; SECONDARY PREVENTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE-FREE SURVIVAL; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK ASSESSMENT; SECONDARY PREVENTION; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 84983471998     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2015.07.034     Document Type: Review

References (81)

1. Horwich, A., Hugosson, J., de Reijke, T., et al. Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol 24 (2013), 1141–1162.
2. Siegel, R., Ma, J., Zou, Z., Jemal, A., Cancer statistics, 2014. CA Cancer J Clin 64 (2014), 9–29.
3. Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49 (2013), 1374–1403.
4. Harris, W.P., Mostaghel, E.A., Nelson, P.S., Montgomery, B., Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6 (2009), 76–85.
5. Saad, F., Miller, K., Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens. Urol Oncol 32 (2014), 70–79.
6. Gravis, G., Fizazi, K., Joly, F., et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14 (2013), 149–158.
7. Hussain, M., Tangen, C.M., Berry, D.L., et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368 (2013), 1314–1325.
8. Sweeney, C., Chen, Y.H., Carducci, M.A., et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial. J Clin Oncol, 32(suppl 5), 2014.
9. Heidenreich, A., Bastian, P.J., Bellmunt, J., et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65 (2014), 467–479.
10. ® Fort Washington, PA, USA Available at: http://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf Accessed November 5, 2014.
11. Huggins, C., Hodges, C.V., Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43 (1941), 209–223.
12. Labrie, F., Belanger, A., Luu-The, V., et al. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 26 (2005), 361–379.
13. Crawford, E.D., Hormonal therapy in prostate cancer: historical approaches. Rev Urol 6:suppl 7 (2004), S3–S11.
14. Mottet, N., Bastian, P.J., Bellmunt, J., et al. Guidelines on Prostate Cancer. 2014, European Association of Urology, Arnhem, The Netherlands Available at: http://uroweb.org/guideline/prostate-cancer/ Accessed May 11, 2015.
15. Garcia, J.A., Rini, B.I., Castration-resistant prostate cancer: many treatments, many options, many challenges ahead. Cancer 118 (2012), 2583–2593.
16. Karantanos, T., Corn, P.G., Thompson, T.C., Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32 (2013), 5501–5511.
17. Mitsiades, N., A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. Cancer Res 73 (2013), 4599–4605.
18. Shore, N., Mason, M., de Reijke, T.M., New developments in castrate-resistant prostate cancer. BJU Int 109:suppl 6 (2012), 22–32.
19. West, T.A., Kiely, B.E., Stockler, M.R., Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: a systematic review of randomised trials. Eur J Cancer 50 (2014), 1916–1924.
20. Scher, H.I., Buchanan, G., Gerald, W., et al. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 11 (2004), 459–476.
21. Suzman, D.L., Antonarakis, E.S., Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol 6 (2014), 167–179.
22. Boccon-Gibod, L., van der Meulen, E., Persson, B.E., An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. Ther Adv Urol 3 (2011), 127–140.
23. Chen, Y., Clegg, N.J., Scher, H.I., Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 10 (2009), 981–991.
24. Ahmadi, H., Daneshmand, S., Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes. Patient Relat Outcome Meas 5 (2014), 63–70.
25. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 355 (2000), 1491–1498.
26. Lukka, H., Waldron, T., Klotz, L., et al. Maximal androgen blockade for the treatment of metastatic prostate cancer–a systematic review. Curr Oncol 13 (2006), 81–93.
27. Walsh, P.C., Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. J Urol 158 (1997), 1623–1624.
28. Messing, E.M., Manola, J., Yao, J., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 (2006), 472–479.
29. Kunath, F., Keck, B., Rucker, G., et al. Early versus deferred androgen suppression therapy for patients with lymph node-positive prostate cancer after local therapy with curative intent: a systematic review. BMC Cancer, 13, 2013, 131.
30. Klotz, L., Boccon-Gibod, L., Shore, N.D., et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 102 (2008), 1531–1538.
31. Klotz, L., Miller, K., Crawford, E.D., et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol 66 (2014), 1101–1108.
32. Pagliarulo, V., Bracarda, S., Eisenberger, M.A., et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 61 (2012), 11–25.
33. Seidenfeld, J., Samson, D.J., Hasselblad, V., et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 132 (2000), 566–577.
34. Iversen, P., McLeod, D.G., See, W.A., et al. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int 105 (2010), 1074–1081.
35. Tyrrell, C.J., Kaisary, A.V., Iversen, P., et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33 (1998), 447–456.
36. Akakura, K., Bruchovsky, N., Goldenberg, S.L., et al. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 71 (1993), 2782–2790.
37. Bruchovsky, N., Rennie, P.S., Coldman, A.J., et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50 (1990), 2275–2282.
38. Crook, J.M., O'Callaghan, C.J., Duncan, G., et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 367 (2012), 895–903.
39. Goldenberg, S.L., Bruchovsky, N., Gleave, M.E., et al. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 45 (1995), 839–844 discussion: 844-845.
40. Botrel, T.E., Clark, O., dos Reis, R.B., et al. Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis. BMC Urol, 14, 2014, 9.
41. Fizazi, K., Jenkins, C., Tannock, I.F., Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Ann Oncol 26 (2015), 1660–1667.
42. Attard, G., Richards, J., de Bono, J.S., New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 17 (2011), 1649–1657.
43. Labrie, F., Cusan, L., Gomez, J.L., et al. Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer. J Steroid Biochem Mol Biol 113 (2009), 52–56.
44. Massard, C., Fizazi, K., Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res 17 (2011), 3876–3883.
45. Hofland, J., van Weerden, W.M., Dits, N.F., et al. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res 70 (2010), 1256–1264.
46. Antonarakis, E.S., Lu, C., Wang, H., et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371 (2014), 1028–1038.
47. Fizazi, K., Martinez, L.A., Sikes, C.R., et al. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res 8 (2002), 775–781.
48. Cookson, M.S., Roth, B.J., Dahm, P., et al. Castration-resistant Prostate cancer: AUA Guideline. 2014, American Urological Association, Seaford, NY Available at: https://www.auanet.org/common/pdf/education/clinical-guidance/Castration-Resistant-Prostate-Cancer.pdf Accessed November 6, 2014.
49. Basch, E., Loblaw, D.A., Oliver, T.K., et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 32 (2014), 3436–3448.
50. Milecki, T., Antczak, A., Kwias, Z., Milecki, P., The use of luteinizing hormone-releasing hormone analogues is still an indispensable element of therapy in castrate-resistant prostate cancer. Contemp Oncol (Pozn) 18 (2014), 85–89.
51. Sartor, A.O., Tangen, C.M., Hussain, M.H., et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 112 (2008), 2393–2400.
52. Smith, M.R., Antonarakis, E.S., Ryan, C.J., et al. ARN-509 in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC) [ASCO abstract]. J Clin Oncol, 31(suppl 6), 2013.
53. Taplin ME, Chu F, Morrison JP, et al. ARMOR1: safety of galeterone (TOK-001) in a phase 1 clinical trial in chemotherapy naïve patients with castration resistant prostate cancer (CRPC) [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR. Cancer Res. 2012;72(8 suppl):abstr CT-07.
54. Gupta, E., Guthrie, T., Tan, W., Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC). BMC Urol, 14, 2014, 55.
55. Schweizer, M.T., Antonarakis, E.S., Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol 4 (2012), 167–178.
56. Small, E.J., Halabi, S., Dawson, N.A., et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22 (2004), 1025–1033.
57. de Bono, J.S., Logothetis, C.J., Molina, A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364 (2011), 1995–2005.
58. Fizazi, K., Scher, H.I., Molina, A., et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13 (2012), 983–992.
59. Logothetis, C.J., Basch, E., Molina, A., et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 13 (2012), 1210–1217.
60. Sternberg, C.N., Molina, A., North, S., et al. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Ann Oncol 24 (2013), 1017–1025.
61. Basch, E., Autio, K., Ryan, C.J., et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol 14 (2013), 1193–1199.
62. Harland, S., Staffurth, J., Molina, A., et al. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer 49 (2013), 3648–3657.
63. Goodman, O.B. Jr., Flaig, T.W., Molina, A., et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 17 (2014), 34–39.
64. Mulders, P.F., Molina, A., Marberger, M., et al. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Eur Urol 65 (2014), 875–883.
65. Ryan, C.J., Smith, M.R., Fizazi, K., et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16 (2015), 152–160.
66. Tran, C., Ouk, S., Clegg, N.J., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324 (2009), 787–790.
67. Scher, H.I., Fizazi, K., Saad, F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 (2012), 1187–1197.
68. Fizazi, K., Scher, H.I., Miller, K., et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol 15 (2014), 1147–1156.
69. Cella, D., Ivanescu, C., Holmstrom, S., et al. Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial. Ann Oncol 26 (2015), 179–185.
70. Sternberg, C.N., de Bono, J.S., Chi, K.N., et al. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Ann Oncol 25 (2014), 429–434.
71. Beer, T.M., Armstrong, A.J., Rathkopf, D.E., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371 (2014), 424–433.
72. Loriot, Y., Miller, K., Sternberg, C.N., et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol 16 (2015), 509–521.
73. Astellas and Medivation Announce New Enzalutamide Data Presented during Plenary Presentations at the 2015 European Association of Urology Congress Astellas Pharma Inc., Medivation Inc., 2015 Available at: http://www.astellas.com/en/corporate/news/pdf/150325_1_Eg.pdf Accessed July 7, 2015.
74. US Food and Drug Administration. FDA Approves New Treatment for a Type of Late Stage Prostate Cancer. 2012, US Food and Drug Administration, Silver Spring, MD Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm317838.htm Accessed November 5, 2014.
75. Rathkopf, D.E., Morris, M.J., Fox, J.J., et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol 31 (2013), 3525–3530.
76. Fizazi, K., Massard, C., Bono, P., et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol 15 (2014), 975–985.
77. Yu, Z., Cai, C., Gao, S., et al. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin Cancer Res 20 (2014), 4075–4085.
78. ClinicalTrials.gov. A Study of ARN-509 in Men with Non-metastatic Castration-resistant Prostate Cancer (SPARTAN)[NCT01946204]. 2015, National Institutes of Health, Bethesda, MD Available at: https://clinicaltrials.gov/ct2/show/NCT01946204?term=NCT01946204&rank=1 Accessed April 30, 2015.
79. ClinicalTrials.gov. Efficacy and Safety Study of ODM-201 in Men with High-risk Nonmetastatic Castration-resistant Prostate Cancer (ARAMIS)[NCT02200614]. 2015, National Institutes of Health, Bethesda, MD Available at: https://clinicaltrials.gov/ct2/show/NCT02200614?term=NCT02200614&rank=1 Accessed April 30, 2015.
80. ClinicalTrials.gov. A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer (ARMOR2)[NCT01709734]. 2015, National Institutes of Health, Bethesda, MD Available at: https://clinicaltrials.gov/ct2/show/NCT01709734?term=NCT01709734&rank=1 Accessed April 30, 2015.
81. Omlin, A., Pezaro, C., Gillessen Sommer, S., Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. Ther Adv Urol 6 (2014), 3–14.